U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H32N2O2
Molecular Weight 320.4696
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAMYLOFIN

SMILES

CCN(CC)CCNC(C(=O)OCCC(C)C)C1=CC=CC=C1

InChI

InChIKey=RYOOHIUJEJZCFT-UHFFFAOYSA-N
InChI=1S/C19H32N2O2/c1-5-21(6-2)14-13-20-18(17-10-8-7-9-11-17)19(22)23-15-12-16(3)4/h7-11,16,18,20H,5-6,12-15H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C19H32N2O2
Molecular Weight 320.4696
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including http://www.ijrcog.org/index.php/ijrcog/article/view/1419

Camylofin is an antimuscarinic. This medication is used as antispasmodic in biliary colic, renal and ureteric colic, dysmenorrhoea, peptic ulcer and chronic enterocolitis. It is used to treat stomach ache in infants and children. Camylofin should be the first choice and may be preferred over other drugs for cervical dilatation and acceleration of active phase of labor.

Originator

Curator's Comment: refernce retrieved from https://www.ncbi.nlm.nih.gov/pubmed/13331655

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ANAFORTAN

Approved Use

Camylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity.
Primary
ANAFORTAN

Approved Use

Camylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity.
PubMed

PubMed

TitleDatePubMed
[Pharmacology of Avacan].
1951 Apr 6
A study of metabolism of isoamyl alpha-[N-(beta-diethylamino-ethyl)]-aminophenylacetate (avacan).
1956 Mar
Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection.
2007 Jan-Feb
Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis.
2010 Sep
Antispasmodics for labour.
2012 Aug 15
Patents

Sample Use Guides

0.285 to 0.857 mg/kg to be taken every 8 hrs.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:13:00 UTC 2023
Edited
by admin
on Fri Dec 15 17:13:00 UTC 2023
Record UNII
340B6Q764V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAMYLOFIN
INN   WHO-DD  
INN  
Official Name English
ANAFORTAN
Brand Name English
ACAMYLOPHENINE
Common Name English
N-(2-(DIETHYLAMINO)ETHYL)-2-PHENYLGLYCINE, ISOPENTYL ESTER
Common Name English
CAMYLOFINE [MI]
Common Name English
camylofin [INN]
Common Name English
Camylofin [WHO-DD]
Common Name English
CAMYLOFINE
MI  
Common Name English
Classification Tree Code System Code
WHO-VATC QA03DA05
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
WHO-VATC QA03AA03
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
WHO-ATC A03AA03
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
WHO-ATC A03DA05
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID7046415
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
ChEMBL
CHEMBL253592
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-202-0
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
EVMPD
SUB06068MIG
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
DRUG BANK
DB13738
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
DRUG CENTRAL
472
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
MERCK INDEX
m99
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY Merck Index
PUBCHEM
5902
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
SMS_ID
100000081619
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
INN
1182
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
NCI_THESAURUS
C166637
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
WIKIPEDIA
Camylofin
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
FDA UNII
340B6Q764V
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
RXCUI
20136
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY RxNorm
CAS
54-30-8
Created by admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY